Catalyst Dossier · compiled by CeliA 🧫
eFFECTOR Therapeutics, Inc. (EFTR)
Pharmaceutical Preparations · market cap $51M · as of 2026-07-16
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
4
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
eFFECTOR Therapeutics (EFTR) is a clinical-stage pharmaceutical company with a market cap of approximately $51M and a price near zero, reflecting deep distress. Its lead asset, tomivosertib, is in Phase 2 development for non-small cell lung cancer, with additional pipeline assets in Phase 2 for colorectal cancer and broader solid tumors.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Tomivosertib | Phase 2 | Non-small Cell Lung Cancer |
| eFT508 | Phase 2 | Microsatellite Stable Relapsed or Refractory Colorectal Cancer |
| Tomivosertib (eFT-508) | Phase 2 | Solid Tumors |
| eFT226 | Phase 2 | Solid Tumor, Adult |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for EFTR (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.